

Centre for Pharmacoepidemiology, Karolinska Institutet (CPE-KI)

First published: 24/03/2010

Last updated: 23/04/2024

Institution

Educational Institution

Laboratory/Research/Testing facility

Not-for-profit

Institution identification

PURI

<https://redirect.ema.europa.eu/resource/47342>

Institution ID

47342

Institution countries

Sweden

Type of institution

Educational Institution

Laboratory/Research/Testing facility

Not-for-profit

Institution role

Researcher

Institution website

<https://ki.se/en/meds/centre-for-pharmacoepidemiology>

ENCePP partner

Yes

Institution description

CPE is lead by acting director Caroline Öberg. CPE's steering group includes representatives from academia, government agencies, regulatory authorities, pharmaceutical industry and

Stockholm's county council. CPE strives to meet the demands from both national and international stakeholders in society and industry concerning data on drug safety, drug utilization, rational drug use and pharmacogenetics. Sweden has a unique opportunity to meet these demands by using national healthcare databases, bio banks, as well as having high levels of expertise in the fields of epidemiologically, pharmacology and other areas. CPE is mainly focusing on drug safety evaluation using data from the Swedish national registers. We have identified five research areas where we in particular can provide expert competence:

- Chronic diseases and biologics
- CNS and drugs
- Drugs during pregnancy and infancy
- Cardiovascular diseases and drugs
- Cancer and drugs.

Institution details

Experience with collecting data directly from individual patients or respondents:

Yes

Interest in carrying out research that is funded by pharmaceutical companies:

Yes

Contact

Ulrika Undén

Main

ulrika.unden@ki.se

Johan Reutfors

Alternate

johan.reutfors@ki.se